Trachea Stent

Trachea Stent Market Outlook

The global trachea stent market is anticipated to reach approximately USD 1.5 billion by 2035, growing at a CAGR of about 6.8% during the forecast period from 2025 to 2035. The increasing prevalence of respiratory disorders such as tracheal stenosis, tumors, and other obstructive airway conditions is a significant factor driving market growth. Coupled with advancements in medical technology and a growing geriatric population, which is more susceptible to these conditions, the demand for tracheal stents is expected to rise substantially. Additionally, the increasing number of minimally invasive surgical procedures is further contributing to the expansion of this market. The rising healthcare expenditure and the growing number of healthcare facilities are also key elements that are expected to positively influence market development. Innovations in stent designs, materials, and drug-eluting capabilities are enhancing patient outcomes, thereby fueling the market's growth.

Growth Factor of the Market

One of the primary growth factors for the trachea stent market is the rising incidence of chronic respiratory diseases, which are often linked to lifestyle choices such as smoking, air pollution, and occupational hazards. The World Health Organization (WHO) has reported a significant rise in respiratory diseases globally, creating a pressing need for effective treatment options, including tracheal stenting. Furthermore, the advancements in manufacturing techniques and materials science are facilitating the development of more effective, durable, and biocompatible tracheal stents, which are leading to improved patient outcomes and satisfaction. The shift towards outpatient procedures and the rising preference for minimally invasive surgeries are also contributing factors, as they often require stenting solutions that can be easily deployed and retrieved. Additionally, the growing awareness and availability of healthcare resources in developing regions are prompting increased acceptance and utilization of these medical devices. As a result, the market is witnessing a robust surge due to the combined effects of these factors.

Key Highlights of the Market

• The trachea stent market is expected to grow at a CAGR of 6.8% from 2025 to 2035.
• Self-expandable stents represent the largest segment by product type, driven by ease of use and effectiveness.
• North America dominates the market due to advanced healthcare infrastructure and increased research activities.
• Hospital end-users are expected to account for a significant share of the market, owing to the rise in complex respiratory procedures.
• Drug-eluting stents are gaining traction for their potential to reduce stent-related complications.

By Product Type

Self-Expandable Stents:

Self-expandable stents are designed to expand automatically upon deployment which makes them particularly advantageous for treating tracheal stenosis. These stents are often made of metal and feature a unique structure that allows them to conform to the shape of the trachea, thus providing optimal support. They are favored in various clinical settings due to their ease of use and effectiveness in maintaining airway patency. The self-expanding feature decreases the risk of airway obstruction post-insertion, making them a reliable option for patients with compromised airways. The ongoing technological advancements in self-expandable stents are expected to further enhance their efficacy and expand their clinical applications in treating complex tracheal conditions.

Balloon-Expandable Stents:

Balloon-expandable stents require a balloon catheter for deployment and are typically used in cases where a more rigid structure is necessary to overcome severe tracheal collapse or obstruction. These stents are preferred in patients with tracheal tumors or significant stenosis where precise control over the stent's diameter is crucial. The balloon-expandable mechanism allows for a controlled expansion, providing a more tailored fit to individual anatomical variations. This adaptability makes them a valuable tool in interventional pulmonology. As advancements in balloon technology continue to evolve, these stents are expected to gain further traction in the clinical setting, with improved designs aimed at minimizing trauma and enhancing patient recovery times.

Hybrid Stents:

Hybrid stents combine features of both self-expandable and balloon-expandable stents, offering the best of both worlds in terms of ease of placement and structural support. They are typically used in complex cases where conventional stenting approaches may not suffice. The hybrid design allows for a more customized fit, which is critical in the irregular anatomy of the tracheobronchial tree. This versatility makes hybrid stents particularly useful in challenging cases, including those involving extensive airway pathologies. As clinical experiences and outcomes with hybrid stents become more documented, their adoption is expected to increase, showcasing their potential to revolutionize treatment protocols for difficult airway obstructions.

Covered Stents:

Covered stents are designed with a protective layer that helps prevent tissue ingrowth and offers a barrier against the tracheal lining. This characteristic makes them particularly beneficial for conditions where stent occlusion due to tissue hyperplasia is a concern. Covered stents are often employed in patients with tracheal tumors or severe stenosis where preventing blockage is critical for maintaining airway integrity. The advancements in biomaterials used in covered stents enhance their durability and biocompatibility, making them a preferred choice for prolonged use. Therefore, the covered stent segment is anticipated to grow, driven by their efficacy in managing complex airway conditions while minimizing complications associated with traditional stenting techniques.

Drug-Eluting Stents:

Drug-eluting stents are an innovative advancement in tracheal stenting, delivering therapeutic agents that help prevent restenosis and improve healing processes. These stents release medication over time to reduce inflammation and inhibit excessive tissue growth, which is a common issue in traditional stenting methods. The potential for reduced complications and improved patient outcomes positions drug-eluting stents as a compelling choice for the management of tracheal stenosis. As research continues to explore effective drug combinations and release mechanisms, the market for drug-eluting stents is expected to expand rapidly, particularly among patients with a high risk of stent failure due to tissue response.

By Application

Tracheal Stenosis:

Tracheal stenosis is characterized by narrowing of the trachea, which can lead to significant respiratory distress. Stenting becomes essential in managing this condition to ensure that the airway remains open for effective breathing. The increasing incidence of tracheal stenosis, particularly among individuals with a history of prolonged intubation or tracheostomy, has driven demand for trachea stents specifically designed to treat this condition. The ability of stents to provide immediate relief and long-term management makes them a critical tool in the therapeutic arsenal for healthcare professionals. Furthermore, ongoing innovations in stent design are aimed at enhancing patient outcomes, thereby creating a positive outlook for the market segment focused on tracheal stenosis.

Tracheal Tumor:

The presence of tumors in the trachea can obstruct airflow, making stenting an essential intervention. Tracheal tumors, whether benign or malignant, necessitate careful management to avoid compromising respiratory function. Stenting provides a minimally invasive option to maintain airway patency while other treatments, such as chemotherapy or radiation, are administered. The growing recognition of tracheal stenting as a viable adjunct therapy for tumor management is expected to enhance market growth. As awareness increases about the importance of addressing airway obstruction caused by tumors, the demand for specialized stenting solutions is anticipated to rise significantly in the coming years.

Tracheal Fistula:

Tracheal fistulae, whether congenital or acquired, can lead to severe respiratory complications if not treated adequately. The use of stenting in these cases is critical to provide structural support to the trachea and facilitate healing while minimizing complications. Stenting offers a non-surgical option that can be employed effectively to manage tracheal fistulae, particularly in patients who may not be surgical candidates. The rising incidence of tracheal fistulae due to various underlying conditions is expected to drive growth in this application segment significantly. Advancements in stent materials and designs that cater to the unique challenges posed by fistulae are likely to further enhance the market's potential.

Tracheal Collapse:

Tracheal collapse, often seen in conditions such as tracheomalacia, poses significant challenges for patients, leading to recurrent respiratory issues. Stenting is an effective therapeutic approach to provide support to the tracheal walls and prevent collapse during breathing. The increasing awareness regarding the effectiveness of stenting in managing tracheal collapse is likely to expand the market for this application. The potential for stents to offer temporary or permanent solutions tailored to individual patient needs presents a significant opportunity for growth, particularly as healthcare providers continue to seek innovative management strategies for complex airway disorders.

Others:

The "Others" segment encompasses a range of applications that may necessitate trachea stenting, including cases of trauma or congenital malformations requiring airway support. This segment is expected to see growth due to the increasing recognition of tracheal stenting as a non-invasive solution that can be employed in various clinical scenarios. As the healthcare landscape evolves, the application of tracheal stents in less common but equally critical situations is expected to gain traction. The adaptability of stenting solutions to cater to diverse medical needs highlights their potential to enhance patient care and broaden market applications.

By Material Type

Metal Stents:

Metal stents are widely utilized in the tracheal stenting market due to their strength, durability, and ability to provide adequate support to the trachea in various clinical conditions. These stents are typically made from stainless steel or nickel-titanium alloys, which offer excellent mechanical properties and biocompatibility. The rigidity of metal stents allows them to maintain airway patency effectively, even in challenging cases of tracheal obstruction. As advancements in metal stent designs continue to emerge, including the development of coatings to enhance biocompatibility and reduce complications, the market for metal stents is expected to grow significantly.

Silicone Stents:

Silicone stents offer a flexible and biocompatible alternative to metal stents, making them suitable for patients with specific anatomical requirements. The soft material of silicone stents allows for greater adaptability within the tracheal lumen, reducing discomfort and minimizing the risk of injury to the tracheal lining. These stents are often utilized in cases requiring temporary airway support, as they can be easily removed and replaced as needed. The ongoing development of advanced silicone materials aimed at enhancing performance and reducing complications is expected to drive the demand for silicone stents in the market.

Bioabsorbable Stents:

Bioabsorbable stents are a novel approach in tracheal stenting, designed to provide temporary support while gradually dissolving in the body over time. This innovative design eliminates the need for a second procedure to remove the stent, thus reducing overall healthcare costs and patient discomfort. Their application is particularly beneficial in patients where long-term stenting is not required or where there is an elevated risk of complications associated with permanent stents. As research continues to validate the efficacy and safety of bioabsorbable stents, their utilization is expected to grow, particularly among younger patients and those with evolving airway needs.

Others:

The "Others" segment includes various specialized materials used in stent production, such as composites or hybrid materials designed to achieve specific performance characteristics. These materials may offer advantages such as enhanced flexibility, increased strength, or unique properties tailored to individual patient needs. As technology advances and research into new materials continues, the adoption of alternative materials in tracheal stenting is likely to increase, providing healthcare professionals with a broader range of options for patient care. This segment's growth potential is underscored by the continuous pursuit of innovation in medical device manufacturing.

By User

Hospitals:

Hospitals are the principal end-users of tracheal stents, primarily due to their comprehensive infrastructure and the availability of specialized medical professionals to perform complex airway procedures. The presence of advanced medical technology and multidisciplinary teams enhances the capacity to manage patients with severe respiratory conditions effectively. With the rising incidence of chronic respiratory diseases and the corresponding increase in tracheal interventions, hospitals are poised to remain the dominant end-user segment in the market. The integration of stenting solutions in hospital protocols is expected to lead to improved patient outcomes and foster a positive growth trajectory for this segment.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) have gained popularity as efficient alternatives for outpatient procedures, including tracheal stenting. These centers allow for minimally invasive procedures that can be completed in a single visit, reducing overall healthcare costs and improving patient convenience. The increasing trend of shifting procedures from hospitals to ASCs is propelling the demand for tracheal stents in this setting. As healthcare providers continue to recognize the advantages of ASCs in terms of patient throughput and reduced recovery times, the market share of tracheal stents utilized in these facilities is expected to expand significantly in the coming years.

Specialty Clinics:

Specialty clinics, particularly those focused on pulmonology or otolaryngology, are playing a growing role in the tracheal stent market. These clinics often provide targeted care for respiratory conditions and have the expertise necessary to conduct stenting procedures effectively. The rise in patient referrals to specialty clinics for advanced airway management is supporting the growth of this end-user segment. As awareness regarding the expertise available within specialty clinics increases, they are likely to capitalize on the growing demand for tracheal stents, thereby contributing positively to the overall market growth.

By Region

North America currently holds the largest share of the trachea stent market, accounting for approximately 40% of the global revenue. This dominance can be attributed to the robust healthcare infrastructure, advanced clinical practices, and a high prevalence of respiratory diseases in the region. The United States, in particular, is experiencing an increasing number of interventional procedures, which is driving up the demand for tracheal stenting solutions. The region is also witnessing significant investments in research and development, leading to innovation, improved stent designs, and enhanced patient outcomes. Furthermore, a growing awareness of advanced medical treatments among healthcare professionals and patients alike is expected to sustain the upward trajectory of the North American market, which is projected to grow at a CAGR of 7% during the forecast period.

Europe is the second-largest market for trachea stents, accounting for around 30% of the global market share. The region benefits from high healthcare expenditure, a well-established medical device industry, and a growing aging population. The increasing focus on improving healthcare quality and patient outcomes is driving the adoption of advanced tracheal stenting solutions across European countries. Moreover, the rising prevalence of chronic respiratory diseases and the growing awareness of minimally invasive surgical options are propelling market growth in Europe. The European tracheal stent market is expected to grow at a CAGR of approximately 6.5%, driven by these favorable conditions and continued investment in healthcare innovation. In contrast, regions such as Asia Pacific and Latin America are also witnessing growth, although at a slower pace, as healthcare systems continue to develop and expand access to advanced medical technologies.

Opportunities

The trachea stent market is ripe with opportunities that can significantly enhance its growth trajectory over the next decade. One of the most promising areas is the increasing focus on research and development aimed at creating advanced stenting solutions. Innovations such as drug-eluting stents, bioabsorbable materials, and customizable designs are all gaining traction among healthcare providers. These advancements not only improve patient outcomes but also create new market segments that can be leveraged for growth. Additionally, the growing emphasis on outpatient procedures and minimally invasive surgical techniques offers a unique opportunity for the trachea stent market to expand its reach. Ambulatory surgical centers and specialty clinics are becoming more prevalent, further increasing the demand for effective stenting solutions tailored to patients requiring timely interventions.

Another significant opportunity lies in the rising awareness and acceptance of tracheal stenting among healthcare providers and patients in developing regions. As healthcare access continues to improve, the demand for advanced respiratory treatments is expected to increase. This opens up new avenues for market penetration and growth, particularly in Asia Pacific and Latin America. Educational initiatives and outreach programs aimed at healthcare professionals can also enhance the understanding of the benefits associated with tracheal stents, driving up acceptance and utilization rates. Furthermore, collaborations between medical device manufacturers and healthcare institutions could foster innovations that meet the specific needs of diverse patient populations, thereby accelerating market growth.

Threats

Despite the promising opportunities in the trachea stent market, several threats could pose challenges to its growth. One of the primary concerns is the potential for complications associated with stenting procedures, including infections, stent migration, and the risk of restenosis. These complications can lead to increased healthcare costs and, in some cases, may deter healthcare providers from utilizing stenting solutions. Additionally, regulatory hurdles associated with the approval of new stent designs and materials could slow down the introduction of innovative products to the market. Stringent regulations can significantly increase the time and cost of bringing new devices to market, which may disadvantage companies that are slower to adapt to changing regulatory environments. Furthermore, the presence of alternative treatment options, such as surgical interventions or newer therapeutic approaches, could pose competitive threats to the market, potentially leading to decreased demand for tracheal stents.

Another critical factor that could restrain market growth is the variability in reimbursement policies across different regions and healthcare systems. Inadequate reimbursement for stenting procedures can limit access to these devices for patients, particularly in regions with less developed healthcare frameworks. This inconsistency can create disparities in care and limit the potential market for tracheal stents. Moreover, economic downturns or healthcare budget cuts may lead to reduced investment in medical technologies, further restraining market growth. In order to navigate these threats, stakeholders in the trachea stent market must adapt to evolving regulatory landscapes, engage in proactive risk management, and advocate for favorable reimbursement policies that promote access to advanced respiratory treatments.

Competitor Outlook

• Boston Scientific Corporation
• Medtronic plc
• Cook Medical
• Conmed Corporation
• Bard Peripheral Vascular
• Teleflex Incorporated
• Hollister Incorporated
• EndoChoice, Inc.
• Biotronik SE & Co. KG
• Hologic, Inc.
• Merit Medical Systems, Inc.
• W.L. Gore & Associates, Inc.
• Cardinal Health, Inc.
• Microbot Medical Inc.
• Terumo Corporation

The competitive landscape of the trachea stent market is characterized by a mix of established global players and emerging companies focused on developing innovative solutions. Major players such as Boston Scientific Corporation, Medtronic plc, and Cook Medical are at the forefront of this market, leveraging their extensive portfolios and strong research and development capabilities to gain a competitive edge. These companies are continually investing in new technologies and innovations, aiming to enhance stenting efficacy while addressing the evolving needs of healthcare professionals and patients alike. Furthermore, collaborations and strategic partnerships among these leading firms are expected to amplify their market position and drive growth through shared resources, expertise, and access to broader distribution channels.

In addition to established companies, several emerging players are entering the trachea stent market, introducing novel products designed to meet specific clinical needs. Companies such as Biotronik SE & Co. KG and Hologic, Inc. are focusing on developing advanced materials and technologies that enhance the performance of tracheal stents. These innovations include bioabsorbable stents and drug-eluting designs that promise to improve patient outcomes while minimizing complications. The entry of new competitors is expected to intensify the competitive dynamics of the market, prompting established firms to accelerate their research efforts and explore new avenues for growth.

As the trachea stent market continues to evolve, significant attention will be paid to regulatory compliance and the ability to navigate the complexities of international markets. Companies that prioritize quality management systems and adhere to stringent regulatory requirements will be better positioned to succeed in this competitive environment. Additionally, the growing emphasis on patient-centric care and improved healthcare outcomes is likely to influence product development strategies. Companies that align their offerings with these trends and actively engage with healthcare providers to understand their needs are expected to gain a competitive advantage in the trachea stent market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Cook Medical
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Hologic, Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Medtronic plc
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 EndoChoice, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Conmed Corporation
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Terumo Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Biotronik SE & Co. KG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Cardinal Health, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Microbot Medical Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Teleflex Incorporated
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hollister Incorporated
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bard Peripheral Vascular
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Merit Medical Systems, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 W.L. Gore & Associates, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Boston Scientific Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Trachea Stent Market, By user
    • 6.1.1 Hospitals
    • 6.1.2 Ambulatory Surgical Centers
    • 6.1.3 Specialty Clinics
  • 6.2 Trachea Stent Market, By Application
    • 6.2.1 Tracheal Stenosis
    • 6.2.2 Tracheal Tumor
    • 6.2.3 Tracheal Fistula
    • 6.2.4 Tracheal Collapse
    • 6.2.5 Others
  • 6.3 Trachea Stent Market, By Product Type
    • 6.3.1 Self-Expandable Stents
    • 6.3.2 Balloon-Expandable Stents
    • 6.3.3 Hybrid Stents
    • 6.3.4 Covered Stents
    • 6.3.5 Drug-Eluting Stents
  • 6.4 Trachea Stent Market, By Material Type
    • 6.4.1 Metal Stents
    • 6.4.2 Silicone Stents
    • 6.4.3 Bioabsorbable Stents
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Trachea Stent Market by Region
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Trachea Stent market is categorized based on

By Product Type

• Self-Expandable Stents
• Balloon-Expandable Stents
• Hybrid Stents
• Covered Stents
• Drug-Eluting Stents

By Application

• Tracheal Stenosis
• Tracheal Tumor
• Tracheal Fistula
• Tracheal Collapse
• Others

By Material Type

• Metal Stents
• Silicone Stents
• Bioabsorbable Stents
• Others

By user

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Boston Scientific Corporation
• Medtronic plc
• Cook Medical
• Conmed Corporation
• Bard Peripheral Vascular
• Teleflex Incorporated
• Hollister Incorporated
• EndoChoice, Inc.
• Biotronik SE & Co. KG
• Hologic, Inc.
• Merit Medical Systems, Inc.
• W.L. Gore & Associates, Inc.
• Cardinal Health, Inc.
• Microbot Medical Inc.
• Terumo Corporation